Literature DB >> 31227170

Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy.

Xuejing Zhang1, Shiwei Niu1, Gareth R Williams2, Jianrong Wu1, Xia Chen1, Hong Zheng3, Li-Min Zhu4.   

Abstract

In this study, we report a novel pH and temperature responsive paclitaxel-loaded drug delivery system based on chitosan and di(ethylene glycol) methyl ether methacrylate. This was functionalized with hyaluronic acid to permit active targeting of CD44-overexpressing human breast cancer cells. The resultant HA-CS-g-PDEGMA-PTX nanoparticles (NPs) have small and uniform sizes (˜170 nm), a high drug loading (13.6 ± 1.3%) and high encapsulation efficiency (76.2 ± 8.5%). Cell viability and confocal microscopy experiments demonstrated that the NPs could effectively target and kill MDA-MB-231 human breast cancer cells, but were much less toxic to healthy human umbilical vein endothelial cells. In vivo biodistribution studies in mice showed that the NPs accumulated in the tumor site, while free drug was distributed more widely and rapidly cleared from the body. Histopathological studies revealed that the NPs led to enhanced apoptosis in the tumor site, which resulted in reduced tumor growth. The NPs prepared in this work have great potential for the treatment of breast cancers, and further offer a platform with which to target other cancers.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer efficacy; Dual-responsive; Hyaluronic acid; Nanoparticles

Mesh:

Substances:

Year:  2019        PMID: 31227170     DOI: 10.1016/j.carbpol.2019.05.081

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  9 in total

1.  Folic Acid and PEI Modified Mesoporous Silica for Targeted Delivery of Curcumin.

Authors:  Xiaoxiao Sun; Nan Wang; Li-Ye Yang; Xiao-Kun Ouyang; Fangfang Huang
Journal:  Pharmaceutics       Date:  2019-08-23       Impact factor: 6.321

2.  Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis.

Authors:  Wenfang Guo; Letai Yi; Baochang Zhou; Minhui Li
Journal:  Nutr J       Date:  2020-12-01       Impact factor: 3.271

Review 3.  Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery.

Authors:  Sergio Andrés Torres-Pérez; Cindy Estefani Torres-Pérez; Martha Pedraza-Escalona; Sonia Mayra Pérez-Tapia; Eva Ramón-Gallegos
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

Review 4.  Drug release study of the chitosan-based nanoparticles.

Authors:  Yedi Herdiana; Nasrul Wathoni; Shaharum Shamsuddin; Muchtaridi Muchtaridi
Journal:  Heliyon       Date:  2021-12-24

Review 5.  Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations.

Authors:  Ali Sartaj; Zufika Qamar; Farheen Fatima Qizilbash; Shadab Md; Nabil A Alhakamy; Sanjula Baboota; Javed Ali
Journal:  Polymers (Basel)       Date:  2021-12-15       Impact factor: 4.329

Review 6.  Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies.

Authors:  Valentina Del Genio; Rosa Bellavita; Annarita Falanga; Katel Hervé-Aubert; Igor Chourpa; Stefania Galdiero
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

Review 7.  Chitosan-Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy.

Authors:  Lisa Efriani Puluhulawa; I Made Joni; Khaled M Elamin; Ahmed Fouad Abdelwahab Mohammed; Muchtaridi Muchtaridi; Nasrul Wathoni
Journal:  Polymers (Basel)       Date:  2022-08-20       Impact factor: 4.967

Review 8.  Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment.

Authors:  Yedi Herdiana; Nasrul Wathoni; Shaharum Shamsuddin; I Made Joni; Muchtaridi Muchtaridi
Journal:  Polymers (Basel)       Date:  2021-05-24       Impact factor: 4.329

9.  Lysine-mediated hydroxyethyl starch-10-hydroxy camptothecin micelles for the treatment of liver cancer.

Authors:  Guofei Li; Mingming Zhao; Limei Zhao
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.